{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:30:42Z","timestamp":1746289842128,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>About 70% of women affected by ovarian cancer experience relapse within 2 years of diagnosis. Traditionally, the standard treatment for recurrent ovarian cancer (ROC) has been represented by systemic chemotherapy.<jats:sup>1<\/jats:sup> Recently, several retrospective studies have suggested that secondary cytoreductive surgery could provide better clinical outcomes than chemotherapy alone, in the case of complete tumor cytoreduction.<jats:sup>2,3<\/jats:sup> About 50% of patients with ROC have a pelvic component of the disease and 22% of patients present isolated pelvic recurrence, often involving the rectum.<jats:sup>4,5<\/jats:sup> Minimally invasive secondary cytoreductive surgery is a feasible option and is associated with favorable perioperative outcomes.<jats:sup>6\u20138<\/jats:sup> It is crucial to fully explore the peritoneal cavity before starting cytoreductive procedures in order to confirm the absence of carcinomatosis.<jats:sup>9<\/jats:sup> The robotic system facilitates the identification of anatomical structures and makes it easier to perform complex surgical steps in narrow spaces. It also allows the integrated use of surgical tools such as intraoperative ultrasound and indocyanine green application.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this video, we present the case of a 64-year-old woman who experienced a rectal recurrence of ovarian cancer after a platinum-free interval of 12 months. We describe, in a step-by-step manner, the surgical procedure of a robotic rectosigmoid resection with totally intracorporeal colorectal anastomosis (TICA).<jats:sup>10\u201312<\/jats:sup><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Robotic secondary cytoreduction with complete gross resection was achieved. The patient did not report any intraoperative or postoperative complications. Final histology confirmed ROC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Totally robotic rectosigmoid resection is a feasible option in isolated bowel recurrences. Thanks to continuous technical evolution, robot-assisted surgery has the potential to have a central role in the fight against solid tumors. Integration of multiple pre- and intraoperative technologies allows personalized surgery to be performed for each different patient.<jats:sup>13,14<\/jats:sup><\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-16149-0","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:04:04Z","timestamp":1725462244000},"page":"8952-8953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Robotic Recto-Sigmoid Resection with Total Intracorporeal Colorectal Anastomosis (TICA) in Recurrent Ovarian Cancer"],"prefix":"10.1245","volume":"31","author":[{"given":"Luca","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Santullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Lodoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Certelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Abatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Gallotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"16149_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","volume":"32","author":"T Baert","year":"2021","unstructured":"Baert T, et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol. 2021;32:710\u201325.","journal-title":"Ann Oncol"},{"key":"16149_CR2","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"Harter P, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. New Engl J Med. 2021;385:2123\u201331.","journal-title":"New Engl J Med"},{"key":"16149_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439\u201349.","journal-title":"Lancet Oncol"},{"key":"16149_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1080\/02841850701557255","volume":"48","author":"A Sahdev","year":"2007","unstructured":"Sahdev A, et al. Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol. 2007;48:1038\u201344.","journal-title":"Acta Radiol"},{"key":"16149_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ygyno.2009.05.004","volume":"114","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009;114:173\u20137.","journal-title":"Gynecol Oncol"},{"key":"16149_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/ijgc-2022-003904","volume":"33","author":"C Conte","year":"2023","unstructured":"Conte C, et al. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33:137\u201344.","journal-title":"Int J Gynecol Cancer"},{"key":"16149_CR7","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ejso.2018.08.006","volume":"44","author":"V Gallotta","year":"2018","unstructured":"Gallotta V, et al. Minimally invasive salvage lymphadenectomy in gynecological cancer patients: a single institution series. Eur J Surg Oncol. 2018;44:1568\u201372.","journal-title":"Eur J Surg Oncol"},{"key":"16149_CR8","doi-asserted-by":"publisher","first-page":"102391","DOI":"10.1016\/j.bpobgyn.2023.102391","volume":"90","author":"V Gallotta","year":"2023","unstructured":"Gallotta V, et al. Robotic surgery in ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2023;90:102391.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"16149_CR9","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.3390\/cancers15194769","volume":"15","author":"C Certelli","year":"2023","unstructured":"Certelli C, et al. Minimally-invasive secondary cytoreduction in recurrent ovarian cancer. Cancers. 2023;15:4769.","journal-title":"Cancers"},{"key":"16149_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ygyno.2019.02.029","volume":"153","author":"J-H Son","year":"2019","unstructured":"Son J-H, et al. Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: close rectal dissection versus total mesorectal excision. Gynecol Oncol. 2019;153:362\u20137.","journal-title":"Gynecol Oncol"},{"key":"16149_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10151-020-02405-4","volume":"25","author":"F Santullo","year":"2021","unstructured":"Santullo F, et al. Totally intracorporeal colorectal anastomosis after segmental sigmoid resection with inferior mesenteric artery preservation for deep infiltrating endometriosis. Tech Coloproctol. 2021;25:745\u20136.","journal-title":"Tech Coloproctol"},{"key":"16149_CR12","first-page":"E294","volume":"276","author":"N Dohrn","year":"2022","unstructured":"Dohrn N, et al. Intracorporeal versus extracorporeal anastomosis in robotic right colectomy: a multicenter, triple-blind. Random Clin Trial Ann Surg. 2022;276:E294.","journal-title":"Random Clin Trial Ann Surg"},{"key":"16149_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1029976","author":"E de Bree","year":"2022","unstructured":"de Bree E, Michelakis D, Anagnostopoulou E. The current role of secondary cytoreductive surgery for recurrent ovarian cancer. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1029976.","journal-title":"Front Oncol"},{"key":"16149_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","volume":"134","author":"M Petrillo","year":"2014","unstructured":"Petrillo M, et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134:257\u201361.","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16149-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:05:26Z","timestamp":1731071126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16149-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":14,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16149"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16149-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anna Fagotti has undertaken relevant financial activities, outside the submitted work, for AstraZeneca\/MSD, Johnson & Johnson, Fondazione Internazionale Menarini, GlaxoSmithKline, Oncoinvent, and Covidien\/Medtronic. Luca Palmieri, Francesco Santullo, Claudio Lodoli, Camilla Certelli, Carlo Abatini, Andrea Rosati, Riccardo Oliva, Giovanni Scambia, and Valerio Gallotta have no disclosures to declare that may be relevant to the contents of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}